Fig. 5: SC66 inhibits 786-O xenograft tumor growth in SCID mice.

786-O tumor-bearing SCID mice (eight mice per group, n = 8) were orally administrated with SC66 (10/25 mg/kg body weight, daily, for 24 days) or vehicle control (“Vehicle”), tumor volumes (a) and mice body weights (d) were recorded every 6 days. Estimated daily tumor growth was calculated as described (b). At Day-36, tumors were isolated and weighted (c). At treatment Day-6, two hours after SC66 (25 mg/kg) or vehicle administration, three 786-O tumors (n = 3) of each group (total six tumors) were isolated; Expression of listed proteins in tumor lysates was tested by Western blotting assays (e and h); The relative SphK1 activity (f) and ceramide contents (g) in tumor lysates were tested as well. The quantified results integrating all three sets of blotting data were presented (e and h). Data were expressed as the mean ± standard deviation (S.D.). *P < 0.05 vs. “Vehicle” group.